IP Library › Granted Patent US 9,272,055
Granted Patent B2
US 9,272,055 · App. 14/007,298 · Granted Mar 1, 2016

Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles

Inventor: Massoud Akhtari (Pasadena, CA)
Assignee: The Regents of the University of California
A61K49/10A61K31/132A61K31/133A61K31/136A61K31/145A61K31/167A61K31/277A61K31/427A61K31/428A61K31/44A61K31/444A61K31/4439A61K31/472A61K31/4745A61K49/1833
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,272,055
App. No.
14/007,298
Granted
Mar 1, 2016
Kind
B2
Abstract

The present disclosure provides functionalized magnetic nanoparticles (MNPs) comprising a functional group that binds to β-amyloid deposits and/or neurofibrillary tangles. The present disclosure provides compositions comprising the functionalized MNPs, and methods of using the functionalized MNPs in imaging β-amyloid deposits and neurofibrillary tangles.

Claims (13)

1. A pharmaceutical composition comprising:

a) a functionalized magnetic nanoparticle (MNP) comprising a magnetic core and a functional group that binds aggregated β-amyloid protein and/or neurofibrillary tangles, wherein said functional group is coupled via an epoxy group to the magnetic core, wherein said functionalized magnetic nanoparticle is capable, when introduced into the bloodstream of a mammalian subject, of crossing the blood-brain barrier of a mammalian subject, and wherein the functional group is 2-(1-{6-[(2-hydroxyethyl)(methy)amino]-2-naphthyl}lethylidene)malononitrile(HODDNP), or a derivative or analog thereof; and

b) a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1 , wherein the HODDNP functional group is coupled to the magnetic core via the hydroxyl group of HODDNP.

3. The pharmaceutical composition of claim 1 , wherein the functionalized MNP further comprises a therapeutic agent.

4. The pharmaceutical composition of claim 1 , wherein the functionalized MNP is encapsulated in an albumin matrix.

5. The pharmaceutical composition of claim 1 , wherein the functionalized MNP comprises an apolipoprotein.

6. The pharmaceutical composition of claim 1 , wherein the functionalized MNP comprises poly(butyl cyanoacrylate) (PBCA).

7. The pharmaceutical composition of claim 6 , wherein the functionalized MNP is attached to the surface of a PBCA particle.

8. The pharmaceutical composition of claim 1 , wherein the functionalized MNP comprises a surfactant.

9. The pharmaceutical composition of claim 8 , wherein the surfactant is selected from polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monostearate, and polyoxyethylene sorbitan monolaurate.

10. The pharmaceutical composition of claim 8 , wherein the surfactant is a block copolymer of polyethylene oxide and polypropylene oxide.

11. The pharmaceutical composition of claim 8 , wherein the functionalized MNP comprises a poloxamine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2014
From: AKHTARI, MASSOUD
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 032702/0904 →
Continuity (2)
Provisional Application 61477958 · Apr 21, 2011
Related Publication 20140140932A1 · May 22, 2014